Navigation Links
ViroPharma Announces Support by Advisory Committee of The Office of Generic Drugs Proposed Guidelines for Developing Generic Versions of Oral Vancomycin Hydorchloride
Date:8/4/2009

term care patients, or those that have a serious underlying illness, are at greatest risk to contract the disease. Patients with this disease have GI tract conditions that are significantly different from those of a healthy individual due to infection. Typical symptoms include diarrhea, fever, nausea and abdominal pain and dehydration, though cases can lead to life threatening complications such as megacolon, peritonitis and perforation of the colon.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. ViroPharma commercializes Cinryze(TM) (C1 esterase inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. diff.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. ViroPharma Incorporated Reports Second Quarter 2009 Financial Results
2. ViroPharma to Release 2009 Second Quarter Financial Results on July 29, 2009
3. ViroPharma Announces Appointment of Frank Baldino, Jr., Ph.D. to Board of Directors
4. ViroPharma Announces Meeting of FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology on Bioequivalence Recommendations for Oral Vancomycin Hydrochloride Products
5. ViroPharma to Present at Two May Healthcare Conferences
6. ViroPharma to Present at the Cowen & Company 29th Annual Healthcare Conference
7. ViroPharma to Host Investor Teach-In Educational Symposium on Hereditary Angioedema
8. ViroPharma to Release 2008 Fourth Quarter and Full Year Financial Results on February 24, 2009
9. ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
10. ViroPharma to Present at the 27th Annual J.P. Morgan Healthcare Conference
11. ViroPharma Provides Update on Vancocin(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... TX (PRWEB) December 20, 2014 The ... a new injectable filler from respected cosmetic brand Juvéderm. ... occur naturally with age. The Medspa at Hendrick is ... development in skin care technology to its clients. , ... gel to be FDA-approved to treat the mid-face and ...
(Date:12/19/2014)... (HealthDay News) -- All children should have their eyesight ... every year, eye experts say. The new vision-screening ... of the U.S. National Center for Children,s Vision Health. ... group require screening for eye problems, particularly vision ... ("lazy eye") and strabismus (a disorder of eye alignment). ...
(Date:12/19/2014)... -- The cost of cancer treatment can cause financial ... Researchers examined data from 1,000 people in the ... lung cancer. Of those patients, almost 900 had finished ... had advanced cancer. Nearly half of the patients ... which was linked with a poorer health-related quality of ...
(Date:12/19/2014)... Dennis Thompson HealthDay ... -- Ebola,s entrance into the United States -- along ... mumps outbreak -- have highlighted cracks in the nation,s ... new health policy report released Thursday. Half of ... respond to infectious disease outbreaks. That was the main ...
(Date:12/19/2014)... NJ (PRWEB) December 19, 2014 ... Inside Patient Care: Pharmacy & Clinics™, an independent ... healthcare team treating and caring for patients inside ... primary care expands to provide optimal access to ... offers a forum for the team treating and ...
Breaking Medicine News(10 mins):Health News:Breakthrough New Injectable Dermal Filler Voluma XC Offered by The MedSpa at Hendrick 2Health News:Preschoolers Need Eye Screening, Experts Say 2Health News:Cancer Treatment Costs Weigh Heavily on Patients, Study Finds 2Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 2Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 3Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 4Health News:The Transformation of Retail Pharmacies into a Healthcare Delivery Center 2Health News:The Transformation of Retail Pharmacies into a Healthcare Delivery Center 3
... People who suffer from the problem of excessive sweating ... have a relief from their condition. Researchers from Saint ... treatment with Botox (botulinum toxin type A) could be ... the first long-term study of repeated treatment with Botox? ...
... like learning and impulsive behavior.// ,The research, ... said that it would help shed light on the impulsive ... and his team at the University of Pittsburgh, Pennsylvania, who ... of the brain in a group of rats to examine ...
... a recent study researchers say that latest research suggests ... be ineffective for women who lack a gene called ... fertility drugs did not improve ovulation rates in mice ... The estrogen receptor beta is one of two estrogen ...
... school children from Denmark, Estonia and Portugal// reported that ... compared to children from children’s of rich and better-educated ... British Medical Journal. The results of the study challenge ... social circumstances in childhood may cause an increased risk ...
... how the heart fails, and hope that this may make ... worked to find out how the metabolic pathways differentiate in ... early stages of heart failure, the heart uses too much ... doesn't use enough fat., ,Gary Lopaschuk, a pharmacologist and ...
... registers its win against polio as the number of cases //reported ... the year 2002. , ,UNICEF, and an army of health ... leading the war against polio in India. Of the 1918 ... India alone, and 1242 cases were registered in Uttar Pradesh. This ...
Cached Medicine News:Health News:Good News For Those Suffering From Excessive Sweating 2Health News:Good News For Those Suffering From Excessive Sweating 3Health News:Regular Use Of Cocaine Can Impair Brain Functions 2Health News:New Discovery May Help Treat Infertility 2Health News:Details Of Heart Failure Discovered 2Health News:Intense Fight Against Polio In India Gets Results 2
(Date:12/17/2014)... -- , The new Dompé ... information concerning the biopharmaceutical Group,s national and international clinical research ... the recently launched institutional website that is receiving accolades from ... a new chapter in the fascinating story of Drug Discovery ... panoramic hub on the world of clinical research, ranging from ...
(Date:12/17/2014)... N.J. , Dec. 17, 2014  IGI Laboratories, ... today the closing of its offering of $125 million ... 2019 (the "Notes").  The Notes were offered and sold ... under the Securities Act of 1933, as amended (the ... a fixed rate of 3.75% per year, payable semiannually ...
(Date:12/17/2014)... and RALEIGH, N.C. ... Marketing Communications, LLC (CTMC), and Integrated Clinical Trial ... recruitment and retention for clinical trials announce that ... Clinical Trial Marketing Services (i-CTMS). i-CTMS will provide ... services to pharmaceutical, biotechnology and medical device companies. ...
Breaking Medicine Technology:Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3
... HAIKOU, China , April 22 /PRNewswire-Asia-FirstCall/ ... (OTC Bulletin Board: KURU), a,leading bio-pharmaceutical company in ... peptide-based drugs and small molecule drugs, today,announced the signing ... of preferred stock and warrants with Caduceus Asia ...
... CardioGenics Inc. (OTC Bulletin Board: CGNH), a developer of technology and ... spotlighted in three publications during the month of April: Today,s Medical ... Transcript . , , ... the April 2010 print and online editions of Today,s ...
Cached Medicine Technology:Kun Run Biotechnology, Inc. Executes Purchase Agreements for Approximately $8 Million Private Placement 2Kun Run Biotechnology, Inc. Executes Purchase Agreements for Approximately $8 Million Private Placement 3Kun Run Biotechnology, Inc. Executes Purchase Agreements for Approximately $8 Million Private Placement 4CardioGenics to be Spotlighted in Three Publications During Month of April 2CardioGenics to be Spotlighted in Three Publications During Month of April 3CardioGenics to be Spotlighted in Three Publications During Month of April 4
For the quantitative determination of Uric Acid in serum. Linearity: 25 mg/dl....
... for continuous, random access operation, the Elecsys ... to large volume laboratories that want to ... the simplicity, flexibility and Stat capabilities of ... be adapted to the changing needs of ...
The Dimension RxL Max is an integrated chemistry system and is the most powerful and technologically advanced Dimension analyze with new standard for excellence in clinical diagnostics. Simply put, t...
... The SkanWasher 400 ... 96-well microplate washer with ... pumps. The individual pressure ... a very gentle wash ...
Medicine Products: